Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.
Open accessThe DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with idiopathic pulmonary fibrosis, treatment with nerandomilast stabilized lung function over a period of 12 weeks. METHODS: In this phase 3, double-blind trial, we randomly assigned patients with idiopathic pulmonary fibrosis in a 1:1:1 ratio to receive nerandomilast at a dose of 18 mg twice daily, nerandomilast at a dose of 9 mg twice daily, or placebo, with stratification according to background antifibrotic therapy (nintedanib or pirfenidone vs. none). The primary end point was the absolute change from baseline in forced vital capacity (FVC), measured in milliliters, at week 52. RESULTS: A total of 1177 patients underwent randomization, of whom 77.7% were taking nintedanib or pirfenidone at enrollment. Adjusted mean changes in FVC at week 52 were -114.7 ml (95% confidence interval [CI], -141.8 to -87.5) in the nerandomilast 18-mg group, -138.6 ml (95% CI, -165.6 to -111.6) in the nerandomilast 9-mg group, and -183.5 ml (95% CI, -210.9 to -156.1) in the placebo group. The adjusted difference between the nerandomilast 18-mg group and the placebo group was 68.8 ml (95% CI, 30.3 to 107.4; P<0.001), and the adjusted difference between the nerandomilast 9-mg group and the placebo group was 44.9 ml (95% CI, 6.4 to 83.3; P = 0.02). The most frequent adverse event in the nerandomilast groups was diarrhea, reported in 41.3% of the 18-mg group and 31.1% of the 9-mg group, as compared with 16.0% in the placebo group. Serious adverse events were balanced across trial groups. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, treatment with nerandomilast resulted in a smaller decline in the FVC than placebo over a period of 52 weeks. (Funded by Boehringer Ingelheim; FIBRONEER-IPF ClinicalTrials.gov number, NCT05321069.).
Overview
CoChat Summary
TL;DR
In this phase 3, double-blind trial, nerandomilast (BI 1015550), an oral preferential phosphodiesterase 4B inhibitor, reduced the 52-week decline in forced vital capacity compared with placebo in patients with idiopathic pulmonary fibrosis. Both the 18-mg and 9-mg twice-daily doses were superior to placebo, with diarrhea the most frequent adverse event.
Key findings
- Adjusted mean change in FVC at week 52 was −114.7 ml (95% CI, −141.8 to −87.5) with nerandomilast 18 mg, −138.6 ml (95% CI, −165.6 to −111.6) with nerandomilast 9 mg, and −183.5 ml (95% CI, −210.9 to −156.1) with placebo.
- Adjusted difference versus placebo was 68.8 ml (95% CI, 30.3 to 107.4; P<0.001) for the 18-mg dose and 44.9 ml (95% CI, 6.4 to 83.3; P=0.02) for the 9-mg dose.
- Diarrhea was the most frequent adverse event in the nerandomilast groups: 41.3% (18 mg) and 31.1% (9 mg) versus 16.0% with placebo; serious adverse events were balanced across trial groups.
- Of 1177 randomized patients, 77.7% were taking nintedanib or pirfenidone at enrollment.
Methods
- Phase 3, double-blind trial; patients with idiopathic pulmonary fibrosis were randomly assigned 1:1:1 to nerandomilast 18 mg twice daily, nerandomilast 9 mg twice daily, or placebo.
- Randomization was stratified according to background antifibrotic therapy (nintedanib or pirfenidone vs. none).
- Primary end point: absolute change from baseline in FVC (milliliters) at week 52; 1177 patients underwent randomization. (Funded by Boehringer Ingelheim; FIBRONEER-IPF, NCT05321069.)
Limitations
- Not stated in the paper (the provided text is the structured abstract and does not report a limitations section).
- Evident from the text: only the primary end point and the most frequent adverse event are reported here, with no detail on secondary outcomes, subgroup analyses, or the full safety profile; the abstract also does not report patient baseline characteristics or trial duration beyond the 52-week end point.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 12 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the adjusted difference between the nerandomilast 9-mg group and the placebo group was 44.9 ml (95% CI, 6.4 to 83.3; P = 0.02)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“-183.5 ml (95% CI, -210.9 to -156.1) in the placebo group”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted difference between the nerandomilast 18-mg group and the placebo group was 68.8 ml (95% CI, 30.3 to 107.4; P<0.001)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adjusted mean changes in FVC at week 52 were -114.7 ml (95% confidence interval [CI], -141.8 to -87.5) in the nerandomilast 18-mg group”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most frequent adverse event in the nerandomilast groups was diarrhea, reported in 41.3% of the 18-mg group and 31.1% of the 9-mg group, as compared with 16.0% in the placebo group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
3 more claims
Create a free account to see all 13 claims and every source verdict.
- Borderline: one of the tests for a substantial claim is unclear. 1
- Probably not a substantial claim. 3
- It may state two separate claims as one. 2
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The approved anti-fibrotic drugs nintedanib (Ofev®), pirfenidone (Esbriet®), and nerandomilast (Jascayd®) slow the rate of FVC decline2,4, but do not halt disease progression or restore lung function.”
From Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study (2026) · cites this paper as [4]
Experimental — accuracy not yet measured
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationGraham, B. L., Steenbruggen, I., Miller, M. R., Barjaktarevic, I. Z., Cooper, B. G., Hall, G. L., Hallstrand, T. S., Kaminsky, D. A., McCarthy, K., McCormack, M. C., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1590st · Cited by 4,305
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Self-citationStandardisation of the single-breath determination of carbon monoxide uptake in the lung
MacIntyre, N., Crapo, R. O., Viegi, G., Johnson, D. C., van der Grinten, C. P. M., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Enright, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034905 · Cited by 2,255
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citationA graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201737 · Cited by 236
Self-citationThe leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis
Selman, M., & Pardo, A. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109482 · Cited by 225
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
Maher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A.-M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2503643 · Cited by 205
Self-citation
Cited by
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
Maher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A.-M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2503643 · Cited by 205
Self-citationInhaled Treprostinil for Idiopathic Pulmonary Fibrosis
Nathan, S. D., Smith, P., Deng, C., Salvo, M. D., Wuyts, W. A., Gallegos, J. P., Song, J. M., Kramer, M. R., King, C., Mackintosh, J. A., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2512911 · Cited by 54
Self-citationLi, W., Xie, Y., Chen, Z., Cao, D., & Wang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1658001 · Cited by 43
Jiang, Y., Zhang, L., Lin, Y., Zhu, X., Wang, T., Zhu, Z., Chen, Y., & Tang, D. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100264 · Cited by 26
Fibroblasts as regulators of lung immunity, repair and fibrosis
Bell, P. T., & Belz, G. T. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01268-4 · Cited by 22
Tissue regeneration: Unraveling strategies for resolving pathological fibrosis
Li, J., Wang, S., Yuan, J., Mao, X., Wang, X., Zhang, L., Dong, Q., Chen, Z., Wang, Y., & Tang, N. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.10.002 · Cited by 23
Systemic sclerosis: pathogenic mechanisms and their implications for treatment
Lescoat, A., Lecureur, V., Gudjonsson, J. E., & Khanna, D. (2025) · Seminars in Immunopathology · doi:10.1007/s00281-025-01065-6 · Cited by 16
Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough
Molyneaux, P. L., Moğulkoç, N., Günen, H., Doboszyńska, A., Kreuter, M., Neustifter, B., Mathur, V. S., Cassella, J. V., CORAL Study Group, Bremner, P. R., et al. (2026) · JAMA · doi:10.1001/jama.2025.26179 · Cited by 12
Self-citationMechanistic basis for the antifibrotic actions of cAMP-based therapies
Peters-Golden, M. L., & Fortier, S. M. (2026) · European Respiratory Review · doi:10.1183/16000617.0265-2025 · Cited by 13
Kondoh, Y., Fujii, T., Inoue, Y., & Atsumi, T. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103900 · Cited by 14
Senhaji, L., Senhaji, N., Abbassi, M., Karhate, M., Serraj, M., Biaze, M. E., Benjelloun, M. C., Ouldim, K., Bouguenouch, L., & Amara, B. (2026) · Biomedicines · doi:10.3390/biomedicines14010090 · Cited by 15
Wang, Y., Sun, D., Dilixiati, N., Wang, D., Song, Y., & Ye, Q. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70240 · Cited by 16
“Nerandomilast , a PDE4B inhibitor with positive Phase III clinical trial results for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), has demonstrated efficacy and is emerging as a promising anti-fibrotic therapy (Maher et al., 2025; Richeldi et al., 2025).”
Jascayd (nerandomilast): a novel PDE4B inhibitor for idiopathic pulmonary fibrosis
Hujjat, S. F. Z., Chandani, H. K., Chandani, D. K., Khan, M. S., & Mahmoud, A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004290 · Cited by 13
Reimagining Fibrosis Research, Outcomes, and Therapeutics Through the Lens of Resolution
Fortier, S. M., Redente, E. F., & Peters-Golden, M. L. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2666-7479 · Cited by 12
“23 It might be argued that such widespread impairments in cAMP signaling are a testament to their importance as anti-fi brotic brakes and are, in fact, necessary for as physiologically disruptive a process as fi brosis to be enabled.”
Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
Nathan, S. D., Smith, P., Deng, C., King, C. S., Salvo, M. D., Weigt, S. S., Pandya, S., Bandyopadhyay, D., Lasky, J. A., Krishna, R., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2501488 · Cited by 29
Self-citationShi, T., Jin, M., Li, H., Ye, Y., Ma, X., Yang, Q., & Zhu, J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126088 · Cited by 7
The importance of mechanical forces in chronic respiratory diseases
Burgess, J. K., Nawroth, J. C., Ibáñez‐Fonseca, A., & Gavara, N. (2026) · European Respiratory Review · doi:10.1183/16000617.0155-2025 · Cited by 10
Brown, M. B. (2026) · Drugs · doi:10.1007/s40265-026-02288-z · Cited by 7
Markov, N. S., Esposito, A. J., Senkow, K. J., Schleck, M. J., Cusick, L., Yu, Z., Sokolenko, Y. V., Diaz, E., Jonasson, E., Swaminathan, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.07.669006 · Cited by 10
“Nerandomilast, a PDE4B inhibitor, has also significantly slowed the rate of FVC decline in patients with idiopathic pulmonary fibrosis and non-IPF ILD 37,38 .”
Tsiri, P., Beltramo, G., Kolb, M. R. J., & Crestani, B. (2025) · European Respiratory Journal · doi:10.1183/13993003.00938-2025 · Cited by 4
Recent and anticipated novel drug approvals (3Q 2025 through 2Q 2026)
Rim, M. H., Joseph, R., Endriukaitis, L. A., Tran, T. B., & Levitsky, A. M. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf237 · Cited by 5
Nerandomilast slows progression of pulmonary fibrosis
Papatriantafyllou, M. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01285-y · Cited by 3
Gogali, A., Κostikas, Κ., & Τzouvelekis, Α. (2025) · European Respiratory Review · doi:10.1183/16000617.0023-2025 · Cited by 6
“…very recently, new evidence has demonstrated the beneficial effects of an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties, called nerandomilast (BI 1015550) in slowing the progression of IPF and of other types of PPF [17, 18].”
Predicting and Treating Pulmonary Fibrosis with Proteomic Biomarker Investigations
Raineri, G., Samarelli, A. V., Tonelli, R., Masciale, V., Aramini, B., Petrachi, T., Bruzzi, G., Gozzi, F., Trasforini, E., Esposito, A., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13112656 · Cited by 5
“Furthermore, a Phase 3 randomized, double-blind, placebo-controlled trial reported that Nerandomilast significantly reduced the decline in FVC over 52 weeks compared to a placebo [14].”
Insight into the pathogenesis of interstitial lung diseases and near-to-native lung fibrosis models
Štefániková, M., Sedláková, V., Portakal, T., Hampl, A., Vaňhara, P., & Doubková, M. (2025) · European journal of medical research · doi:10.1186/s40001-025-03504-4 · Cited by 3
“In clinical trials, nerandomilast showed a positive effect on FVC in patients with progressive pulmonary fibrosis [104] and IPF [105], with smaller FVC declines compared to placebo over a 52-week period [104, 105].”
Zhang, Y. N., Wang, W. N., Liu, G. Q., Wang, L. N., Zhang, X., Mei, J., & Yang, K. N. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl45052 · Cited by 4
Immunological mechanisms underlying fibrotic diseases via single-cell technologies
Koda, Y., Nakamoto, N., & Kanai, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1720047 · Cited by 6
Muscato, G., Libra, A., Reina, C., Gili, E., Fruciano, M., Martella, S., Palmucci, S., Spicuzza, L., Sambataro, G., & Vancheri, C. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04120-6 · Cited by 3
“FVC: Forced Vital Capacity; ppFVC: percent predicted FVC; DLCO: diffusing lung capacity for carbon monoxide; 6MWTD: distance at the 6 min walking test in both PPF and IPF [22, 23].”
Emerging Therapies in Pulmonary Fibrosis
Etchingham-Coll, H., Temizel, E., Okezie-Enyioma, N., Martin, N., Kaenmuang, P., Coghlan, S., Spagnolo, P., & Chaudhuri, N. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00349-y · Cited by 6
Shahzad, H., Afzaal, U., Saleem, F., Gul, A. H., Thummar, F. R., Murtaza, H. N., Gelan, A. A., Ahsan, M., Irfan, R., Nawaz, A., et al. (2026) · The Clinical Respiratory Journal · doi:10.1111/crj.70181 · Cited by 7
“Only a small proportion of participants discontinued treatment due to diarrhea [4, 10, 15, 16].”
InfluentialJuan-Guardela, B. M., & Herazo-Maya, J. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag121 · Cited by 3
Immunological mechanisms and therapeutic approaches in pulmonary fibrosis
Nell, L. M., Hendriks, R. W., Wijsenbeek, M. S., Corneth, O. B. J., & Koudstaal, T. (2026) · European Respiratory Review · doi:10.1183/16000617.0227-2025 · Cited by 5
“In FIBRONEER-IPF [193] and FIBRONEER-ILD [194], the agent significantly slowed the annual decline in FVC, with the ILD cohort also showing a nominal reduction in all-cause mortality.”
Self-citationBai, Z., Lan, T., Hong, W., Que, H., Zhu, M., Xiao, X., Wan, D., Ai, J., Huang, S., Wang, J., et al. (2026) · Nature Immunology · doi:10.1038/s41590-026-02501-x · Cited by 6
Self-citationTGFb signaling instructs a conserved fibrosis-associated cell state marked by LRRC15
Shyer, J. A., Wehbe, F., Davidson, C. D., Bender, H. S., Thai, M., Cox, C., Missarova, A., Arlantico, A., Hall, B. M., Zhang, R., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536550123 · Cited by 4
“Critically, these medications are not universally effective and there is a strong need for novel therapies that slow the progression of disease and/or restore lung function for patients with this debilitating disease (3, 4).”
Progress through Persistence — Turning the Page in Pulmonary Fibrosis Clinical Trials
Lee, J. S. (2025) · New England Journal of Medicine · doi:10.1056/nejme2505760 · Cited by 4
Baas, J. D., Varga, J., Feghali‐Bostwick, C. A., Peters-Golden, M. L., & Fortier, S. M. (2025) · The FASEB Journal · doi:10.1096/fj.202500694rr · Cited by 7
Advances in novel therapeutics for idiopathic pulmonary fibrosis
Li, M., Chen, B., Zhang, X., Zhuo, T., & Liu, X. (2025) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2025.102396 · Cited by 3
Wong, A. W., Marinescu, D.-C., Johannson, K. A., Marcoux, V. S., Fisher, J. H., Assayag, D., Manganas, H., Kolb, M. R. J., Ryerson, C. J., & Guler, S. A. (2025) · European Respiratory Journal · doi:10.1183/13993003.01533-2025 · Cited by 4
Fijołek, J., & Śniady, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134631 · Cited by 3
“Results from the FIBRONEER-IPF trial have been recently published, demonstrating that treatment with nerandomilast resulted in a smaller decline in FVC over 52 weeks compared to placebo ( − 114.7 mL vs. − 183.5 mL) [143].”
InfluentialNerandomilast shatters decade-long stalemate in fibrotic lung diseases: FDA fast track insights
Zhou, A., Lang, Q., Zhao, C., et al. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100151 · Cited by 3
Ziehr, D. R., Li, F., Parnell, K. M., Krah, N. M., Leahy, K. J., Guillermier, C., Gao, C., Prell, S. A., Vigder, N., Poli, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.ads2673 · Cited by 17
Treatable traits in interstitial lung disease: opportunities and challenges
Khor, Y. H., Podolanczuk, A. J., Renzoni, E. A., McDonald, V. M., Cottin, V., Holland, A. E., Inoue, Y., Russell, A., Song, J. W., Wijsenbeek, M. S., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108353 · Cited by 4
Self-citationNerandomilast in Patients with Pulmonary Fibrosis
Maher, T. M., Richeldi, L., & Zoz, D. F. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2510302 · Cited by 2
Self-citationBolger, G. B. (2025) · Life · doi:10.3390/life15101600 · Cited by 6
“Although there is yet no formal classification of pulmonary fibrosis that includes all of the above conditions, current clinical practice includes many of the above factors in decision-making, and, more recently, in the design of clinical trials [18,19,52].”
Afloarei, C. A., Bîrladeanu, T., Pintilie, A.-L., Toma, D., Marcu, D. T. M., Antal, A. Z., Zabara, M., & Crișan-Dabija, R. A. (2025) · Biomedicines · doi:10.3390/biomedicines13112703 · Cited by 8
“Therefore, a possibility arises of additive benefit in fibrosing phenotypes characterized by inflammatory activation [26].”
Sun, D., Cao, X., Sun, J., Zhang, H., & Liu, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1704103 · Cited by 4
Self-citationSnoeck, H. (2025) · European Respiratory Journal · doi:10.1183/13993003.02083-2025 · Cited by 6
Nerandomilast as the first PDE4B-selective therapy in idiopathic pulmonary fibrosis
Ibrahim, M., Piazza, G. A., & Ahsan, F. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.11.006 · Cited by 4
Goda, S., Yamada, T., Goto, Y., Uda, S., Nakao, A., Shiotsu, S., Kukida, Y., Tanimura, K., Miyamoto, A., Imasato, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-34071-7 · Cited by 3
“Other ILD subtypes, such as those classified as progressive fibrosing ILD (PF-ILD) 6 or progressive pulmonary fibrosis (PPF) 1 also feature progressive fibrosis and functional decline‒particularly in forced vital capacity (FVC)‒despite appropriate treatment.”
Interstitial lung abnormalities: to treat or not to treat? The hamlet dilemma
Zanini, U., Franco, G., Pirotta, C., Passeri, E., Mazzotta, S. M., Ferrara, G., Mura, M., Faverio, P., & Luppi, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1762243 · Cited by 2
“In addition to currently approved antifibrotic agents, emerging therapies may further expand future treatment options for fibrotic lung disease (81, 82).”
Kang, H.-X., Fu, Y.-F., Wu, H., Yan, X.-L., Wu, J.-J., Jiang, L.-Z., Wang, L.-S., Xiao, Y.-R., Zhang, Z.-Z., Yuan, F., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1770516 · Cited by 4
Unlocking the potential of mRNA nanomedicines for comprehensive fibrosis therapy
Yang, Y., Li, C., Xiong, W., Li, C., & Xiao, J. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102917 · Cited by 2
“42–44 These findings highlight the potential advantage of dual-pathway intervention that targets both inflammatory and profibrotic processes.”
Poletti, V. E., Ryerson, C. J., & Piciucchi, S. (2026) · European Respiratory Journal · doi:10.1183/13993003.01903-2025 · Cited by 2
Sisson, T. H., Fortier, S. M., Tsoi, L. C., Alonzo, R., Subbotina, N., Warnock, M., Mann, K. M., Gutor, S. S., Hartman, J. C., Gudjonsson, J. E., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6951289/v1 · Cited by 3
Alber, A. B., Kwong, G., Gupta, V. K., Dooley, P. E., Patel, J., Bawa, P., Minakin, K., Jones, D. L., Gopal, D., Souza, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702837 · Cited by 4
Tagami, Y., Kawai, M., Okamura, K., & Kitamura, H. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0021 · Cited by 1
Interstitial Lung Disease in 2025—Progress, Challenges, and Hope Ahead
Sehgal, S., & Mehta, A. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186673 · Cited by 1
“Nerandomilast, a PDE4B inhibitor, recently reached its primary endpoint in a phase three trial, marking the first positive trial of a novel agent since antifibrotics [6].”
Kass-Gergi, S., Holcomb, N. P., Maiden, M. M., Eisenlohr, L. C., & Vaughan, A. E. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00189.2025 · Cited by 2
“A notable bright spot is the PDE4B inhibitor nerandomilast, which in 2025 phase-3 trials slowed FVC decline in both IPF and progressive PF, suggesting an upcoming (welcome) addition to antifibrotic therapeutic regimens pending regulatory decisions (118, 119).”
Smadja, D. M., Nunès, H., Juvin, K., Borie, R., Mauge, L., Crestani, B., Blandinières, A., Carton, Z., Philippe, A., Bertil, S., et al. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10987-5 · Cited by 1
“Indeed, recently Neran - domilast, a selective phosphodiesterase 4B (PDE4B) inhibitor, has demonstrated efficacy in patients with IPF [38, 39 ].”
Thivent, S., Neder, J. A., Bernard, A., Coudurier, M., Guinot, M., Hérengt, F., Vergès, S., & Marillier, M. (2025) · Experimental Physiology · doi:10.1113/ep091542 · Cited by 1
Karayama, M., Miyashita, K., Inoue, Y., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Inui, N., et al. (2025) · Thorax · doi:10.1136/thorax-2025-223430 · Cited by 3
Kumar, A., Abdullah, H., Abbasi, S. U. A. M., Tanvir, A., Ram, F., & Abdullah, F. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000002040 · Cited by 1
Wang, L., Fischmeister, R., & Manoury, B. (2025) · Cells · doi:10.3390/cells14211670 · Cited by 1
“These advances need to be translated into human cells and tissues, while the PDE4B inhibitor BI 1015550 has so far only been tested in patients with idiopathic fibrosis [145,146].”
Nyaupane, U., Johannson, K. A., Kelly, M. M., & Kai, F. (2025) · Experimental Lung Research · doi:10.1080/01902148.2025.2582970 · Cited by 1
Machahua, C., Marti, T. M., Kewalramani, N., Dorn, P., Neubert, L., Petzold-Mügge, C., & Funke-Chambour, M. (2025) · Respiratory Research · doi:10.1186/s12931-025-03389-1 · Cited by 3
“This is highlighted by the recent success of dual anti-inflammatory and anti-fibrotic drugs in PPF and IPF by phospho-diesterase-4 (PDE4) inhibition [17, 18].”
Zhou, X., Lu, T., Xu, R., Wang, C., Chen, S., Chen, J., Chang, X., Li, M., Shi, J., Xu, C., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1676086 · Cited by 2
“Late-phase trials are mixed: pamrevlumab and PRM-151 failed in phase 3, whereas nerandomilast reduced FVC decline and inhaled treprostinil met its primary endpoint-signaling progress yet persistent unmet need (10, 11).”
COVID-19 and Interstitial Lung Disease
Carbone, R. G., Nagoti, S., Monselise, A., Wille, K., Puppo, F., & Shah, P. L. (2025) · Medicina · doi:10.3390/medicina62010022 · Cited by 1
The intersection of liver cirrhosis and pulmonary fibrosis
Bayraktar, E. A., & Salvatore, M. M. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07449-4 · Cited by 4
Singh, P., Patel, P. K., Kasam, R. K., Lawson, R., Ediga, H. H., Jegga, A. G., & Madala, S. K. (2026) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00204.2025 · Cited by 1
“Current therapies, nintedanib (Ofev) and pirfenidone (Esbriet), and the recently approved nerandmilast (Jascayd) have been shown to slow the rate of forced vital capacity decline in clinical trials (8–10).”
Srivali, N., & Giacomi, F. D. (2026) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2026.2612785 · Cited by 1
“The recent development of nerandomilast [37], a novel phosphodiesterase inhibitor with anti-inflammatory and anti-fibrotic properties, raises questions about its potential cancer-protective effects.”
Weyer, R., Völker, K., Potapenko, T., Krebes, L., Abeßer, M., Friedrich, A.-L., Lessmann, E., Khadim, A., Ruppert, C., Agha, E. E., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.196812 · Cited by 2
“Notably, PDE4 inhibitors and prostacyclin agonists had positive results in phase II and III clinical trials by stabilizing lung function in patients with IPF (34), which recently led to the approval of the selective PDE4B inhibitor nerandomilast (Jascayd) by the FDA (35).”
Fares, W. H., & Castagna, M. (2026) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1177/19412711251414386 · Cited by 1
Sebastiani, M., Luppi, F., & Bendstrup, E. M. (2026) · Drugs · doi:10.1007/s40265-025-02282-x · Cited by 1
“Recently, a new antifibrotic drug, nerandomilast, has been investigated in two phase 3, double-blind, randomized trials investigating its efficacy in patients with IPF and PPF [110, 111].”
Combination Therapy in Pulmonary Fibrosis: A New Era
Luppi, F., Ferrara, G., & Vancheri, C. (2026) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2026.01.012 · Cited by 1
Liu, Y., Hu, Y., Se-rigeleng, Yang, Z., Liu, X., Yu, J., Li, H., Gu, S., Yang, W., Yang, C., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1771007 · Cited by 2
“Nerandomilast, a novel phosphodiesterase 4B (PDE4B) inhibitor, has demonstrated signi fi cant ef fi cacy in clinical trials for idiopathic pulmonary fi brosis (IPF) and progressive fi brotic interstitial lung disease (12, 13).”
Self-citationCooley, J. C., Penick, S. K., Wilson, J. A., Javkhlan, N., Foster, D. G., Edelman, B., Schott, C. A., Humphries, S. M., Lynch, D. A., Schwartz, D. A., et al. (2026) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1093/ajrcmb/aanag045 · Cited by 1
Geriatric nutritional risk index in antifibrotic therapy can predict tolerability and mortality risk
Masuda, T., Mochizuka, Y., Suzuki, Y., Kono, M., Matsushima, S., Kato, S., Suzuki, K., Tanaka, K., Koda, K., Masuda, T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-45792-8 · Cited by 1
Okada, A., Nakano, A., Fujita, K., Inoue, Y., Ito, T., Hashiba, F., FUJIKAWA, M., Tanaka, T., Mukai, A., Ito, K., et al. (2026) · Advances in respiratory medicine · doi:10.3390/arm94020024 · Cited by 1
“Neran-domilast, a novel therapeutic agent targeting inflammatory and fibrotic pathways, has been investigated as a potential treatment option for IPF [3].”
Zhong, Y., Xiao, C., Liang, Y., Wang, P., Long, Y., Li, S., Song, N., Shang, W., Yang, W., & Zhang, X. (2026) · Natural Products and Bioprospecting · doi:10.1007/s13659-026-00593-4 · Cited by 1
“…phosphodiesterase 4B (PDE4B) inhibitor that achieved the primary endpoint in phase III clinical trials [11, 12], has been approved by FDA for the treatment of PF. Nerandomilast treatment significantly attenuated the decline of forced vital capacity and was well-tolerated in patients [11, 12].”
Pulmonology: What You May Have Missed in 2025
Gu, Y., Ragheb, S. M., & UNGER, M. W. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00985 · Cited by 1
The immunodynamics of pulmonary fibrosis
Xie, C. H., Ma, Y., Wang, Y., Gul, A., Tang, W., Luo, Q., Xu, W., Wei, Y., Dong, J., & Liu, W. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.04.001 · Cited by 1
Li, J. S., Li, H., Wang, X., Wang, C., Sun, J., Qu, C., & Tian, H. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c01140 · Cited by 1
Vascular targeted therapies for fibrotic lung disease: start of a new era?
Tyker, A., Price, L. C., Nathan, S. D., & Kolb, M. R. J. (2026) · European Respiratory Journal · doi:10.1183/13993003.00285-2026 · Cited by 2
Yang, H., & Tao, X. (2026) · Medical Hypotheses · doi:10.1016/j.mehy.2026.112006 · Cited by 1
New drugs approved by the FDA in 2025: Synthesis and clinical applications
Liu, W., Li, X., Han, Y., Wu, L., Wang, M., Xuan, W., Xu, Z., Liu, W., Zhao, Q., & Hao, S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118952 · Cited by 2
PDE4 Inhibition in Dermatologic Disease: Impacts Beyond Inflammation
Khodadad, K., Chin, N. E., & Chovatiya, R. (2026) · International Journal of Dermatology · doi:10.1111/ijd.70456 · Cited by 3
Tirelli, C., Muscato, G., Alaimo, C., Leo, I. D., Mirijaj, S., Pennisi, F., Vancheri, C., & Mondoni, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114172 · Cited by 2
“Potential drug–drug interactions may influence exposure and dosing, as shown by the interaction between nerandomilast and pirfenidone [82].”
InfluentialWen, K., Zhao, Q., Wang, S. L., Liu, F., Cai, M., Wang, H. Y., Zhou, X., & Xu, Y. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122015 · Cited by 1
USFDA‐Approved Small Molecules in the Year 2025: Medicinal Chemistry Strategies and Trends
Rao, M. P., Anwer, R., Benni, S. D., Babu, M. A., Singh, T., Ahmed, S., Fareed, M., & Bansal, N. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70272 · Cited by 2
Honap, S., Dignass, A. U., Jairath, V., et al. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2695461 · Cited by 1
“More recently, nerandomilast, a preferential phosphodiesterase 4B inhibitor, has shown similar effects in slowing lung function decline in IPF and progressive pulmonary fibrosis [17–19].”
Diagnosis and treatment of idiopathic pulmonary fibrosis: a narrative review
Yoo, J. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0044 · Cited by 1
Mycophenolate and azathioprine in fibrotic interstitial lung disease
Pugashetti, J. V., Jee, A. S., Yu, A. R. M., Hammoud, N., Chua, F., Yazbeck, L., Lee, C. T., Liu, G. Y., Adams, T. N., Adegunsoye, A., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag362 · Cited by 3
Self-citationAl-Abdulraheem, Z., Juppi, H., Morikka, J., Inkala, S., Perho, N., Sani, S., Serra, A., Federico, A., Fratello, M., & Greco, D. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0193
“U. S. Food and Drug Administration (FDA)- approved therapies include nintedanib, pirfenidone, nerandomi-last, ivacaftor, and dupilumab [ 2 – 4 , 23 ], which have demonstrated the ability to decelerate disease progression, but are associated with a range of side and adverse effects, such as upper…”
Cryobiopsy at the dawn of fibrosis: unlocking early diagnosis and therapeutic windows
Carducci, C., Kaminski, N., Justet, A., & Tomassetti, S. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1821109 · Cited by 1
Bos, S., Hellemons, M. E., Dave, K., Engel, M. F. M., Holm, A. M., Morlacchi, L., Müller, V., Pavanello, S., Picard, C., Rossi, V., et al. (2026) · Transplant International · doi:10.3389/ti.2026.16959 · Cited by 2
Yang, M. H., Kim, S., Lee, S. M., Yun, J., Hwang, H. J., Chae, E. J., Seo, J. B., Choe, J., & Kim, H. C. (2026) · Radiology · doi:10.1148/radiol.260703 · Cited by 1
Singh, P., Thampi, G., Gupta, K., Gangte, N., PATTNAIK, B. R., Agrawal, A., & Kukreti, R. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2543473 · Cited by 3
“Three studies [37–42] identified as high-risk were excluded from the analysis.”
Branz, A., Shalashova, I., Funk, A. M., Gensheimer, T., Wytyk, A., Wespel, S. L., Drescher, J., Mayr, C. H., Neubert, L., Kamp, J. C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.29.679236 · Cited by 1
“These findings align with clinical data from nerandomilast, a PDE4 inhibitor, which showed positive outcomes in Phase III trials for IPF and PPF, with strong responses in HMVECs [49–51].”
Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study
Molyneaux, P. L., Hirani, N. A., Chia, C. C. K., Kulkarni, T., Zaman, T., Kaner, R. J., Coelho, A. L., Jannini-Sa, Y. A. P., Windsor, B., Kruger, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75291-3 · Cited by 1
Yan, T., Liu, J., Liu, Y., Gu, W., Liu, J., Li, Y., Lv, R., Zhang, C., Ding, J., Zha, C., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00542-0
“Nerandomilast, a selective PDE4B inhibitor, shows promise in phase II/III trials but remains investigational [6].”
Self-citation
Metadata
- Authors
- Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martinez, F. J., Oldham, J. M., Valenzuela, C., Clerisme-Beaty, E., Gordat, M., Wachtlin, D., Liu, Y., Schlecker, C., Stowasser, S., Zoz, D. F., & Wijsenbeek, M. S.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Nippon Medical School (JP)
- Lyon 1 Université (FR)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University of Southern California (US)
- University of Massachusetts (UMass) Chan Medical School–UMass Memorial Health System, Worcester
- University of Michigan (US)
- Hospital Universitario de La Princesa (ES)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (France) (FR)
- Boehringer Ingelheim (United States) (US)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-12
- Volume
- 392
- Issue
- 22
- Pages
- 2193-2202
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4410472815
- Cited by
- 297
- References
- 20
- Citations by year
- 2026: 231 · 2025: 65
- FWCI
- 175.62
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- nerandomilast, idiopathic pulmonary fibrosis, antifibrotic therapy, nintedanib, pirfenidone, forced vital capacity, lung function, dose comparison, diarrhea, adverse events, antifibrotic agents, immunomodulatory therapy, antiproliferative therapy
- MeSH terms
- Antifibrotic Agents, Administration, Oral, Aged, Cyclobutanes, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Indoles, Lung, Male, Middle Aged, Organic Chemicals, Piperidines, Pyridones, Tablets, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis, Phosphodiesterase 4 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.